Search results
4 days ago · But new criteria could lead to a diagnosis on the basis of a simple blood test. The F.D.A. has given full approval to the Alzheimer’s drug Leqembi. Here is what to know about it.
Jul 6, 2023 · The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.
Jul 24, 2023 · The Food and Drug Administration (FDA) recently granted full approval to a new Alzheimer’s treatment called lecanemab, which has been shown to moderately slow cognitive and functional decline in early-stage cases of the disease.
Jul 17, 2023 · Full results about the Alzheimer's disease drug donanemab have been released today, supporting earlier trial results that suggested the breakthrough drug may slow down the progression of the disease.
Jan 6, 2023 · January 06, 2023. Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the...
Jan 6, 2023 · The Food and Drug Administration on Friday approved an Alzheimer’s drug shown in clinical trials to slow cognitive decline in patients in the early stages of the illness.
Jul 6, 2023 · Leqembi, from Japanese drugmaker Eisai and U.S.-based drugmaker Biogen, targets a type of protein in the brain called beta-amyloid, long thought by scientists to be one of the underlying causes...
FDA approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans, using the Accelerated Approval pathway.
Jul 7, 2023 · The US Food and Drug Administration on Thursday granted traditional full approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course of the memory-robbing disease.
Jul 17, 2023 · CNN — The full approval this month of the Alzheimer’s drug Leqembi marked a historic shift in the treatment of the disease: For the first time, doctors have a medicine to prescribe that has...
